Biofrontera is a biopharmaceutical company focusing on commercialization of pharmaceutical products. Co.'s principal product is Ameluz®, which is a prescription drug approved for use in combination with its licensor's medical device, which has been approved by the U.S. Food and Drug Administration, the BF-RhodoLED® lamp, for photodynamic therapy, or PDT, (when used together, Ameluz® PDT) in the U.S. for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. Co.'s second prescription drug product in its portfolio is Xepi® (ozenoxacin cream, 1%), a topical non-fluorinated quinolone that inhibits bacterial growth. We show 2 historical shares outstanding datapoints in our coverage of BFRI's shares outstanding history.
Understanding the changing numbers of BFRI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BFRI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BFRI by allowing them to research BFRI shares outstanding history
as well as any other stock in our coverage universe. |
Free BFRI Email Alerts:
Video: Shares Outstanding Importance
